CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects

Breast cancer patients with absent or reduced CYP2D6 activity and consequently low endoxifen levels may benefit less from tamoxifen treatment. CYP2D6 poor and intermediate metabolizers may need a personalized increased tamoxifen dose to achieve effective endoxifen serum concentrations, without incre...

Descripción completa

Detalles Bibliográficos
Autores principales: Dezentjé, V. O., Opdam, F. L., Gelderblom, H., Hartigh den, J., Van der Straaten, T., Vree, R., Maartense, E., Smorenburg, C. H., Putter, H., Dieudonné, A. S., Neven, P., Van de Velde, C. J. H., Nortier, J. W. R., Guchelaar, H.-J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589558/
https://www.ncbi.nlm.nih.gov/pubmed/26369533
http://dx.doi.org/10.1007/s10549-015-3562-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589558/
https://www.ncbi.nlm.nih.gov/pubmed/26369533
http://dx.doi.org/10.1007/s10549-015-3562-5

Ejemplares similares